Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

NCT02833142 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Acute Optic Neuritis

Interventions

DRUG: BIIB033 (opicinumab)

Sponsor

Biogen